Cardiovascular Risk Management in T2D with established ASCVD: Current Evidence for Dapagliflozin and Sitagliptin-Dr Piyas Gargari

Type 2 diabetes (T2D) frequently presents with cardiovascular complications already established, with cardiovascular diseases (CVD) accounting for 40–80% of deaths in patients with T2D. Once...